It’s good news in the fight against colorectal cancer: A new test can detect the disease with a simple blood draw. But don’t cancel your colonoscopy just yet — that old standby is still more reliable ...
Studies show higher completion rates for mt-sDNA testing and the positive impact of patient navigation in expanding access to underserved and older populations Exact Sciences Corp. (NASDAQ: EXAS), a ...
The pending $23 billion sale of Madison-based Exact Sciences to health care giant Abbott centers on Exact Sciences' flagship product: colorectal cancer test Cologuard. Exact Sciences markets Cologuard ...
Q. My doctor prescribed a Cologuard test instead of a colonoscopy. No one mentioned how often Cologuard could result in false positive test results, as mine did. So, a colonoscopy was necessary after ...
Cologuard Plus™ test raises the performance bar with sensitivities of 95% for colorectal cancer and 43% for advanced precancerous lesions at 94% specificity Cologuard Plus test will minimize ...
The Cologuard Plus test demonstrated 95% sensitivity for colorectal cancer detection at 94% specificity, making it the most accurate noninvasive CRC screening test reported in studies to date Building ...
With a large portion of people aged 45 and older prone to putting off or completely avoiding recommended colon cancer screenings, Exact Sciences is pitching its noninvasive at-home Cologuard test as a ...
Positive and Negative Predictive Value of a Non-Endoscopic Molecular Barrett’s Esophagus Detection Test in Screening Eligible Adults: Results from a Large Multicenter Population Based Clinical Trial ...
Abbott announced on Thursday, Nov. 20 it plans to buy Exact Sciences, a Madison-based maker of cancer screening and diagnostic tests, in a deal valued at an estimated $23 billion, including debt.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback